insights_auto
Why is BEAM down 2.14%?
Dive Deeperchevron_right
BEAM:NASDAQ
Beam Therapeutics Inc
$24.69
arrow_downward
-2.14%(-0.54) 1D
Oct 7, 11:49:09 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEAM...
Open
$24.64
High
$25.37
Low
$24.45
Mkt. cap
2.55B
Avg. vol.
1.87M
Volume
664.83K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$0.81
Beta
2.20
Shares outstanding
103.29M
No. of employees
540
Open
$24.64
High
$25.37
Low
$24.45
Mkt. cap
2.55B
Avg. vol.
1.87M
Volume
664.83K
52-wk high
$38.26
52-wk low
$20.23
EPS
-$0.81
Beta
2.20
Shares outstanding
103.29M
No. of employees
540
News stories
From web sources and news partners
Investing News Network
·
55 minutes ago
Snorkel AI Raises $350 Million to Help Push the Frontier: NYSE Content Update
Quartz
·
1 hour ago
Dow drops 451 points as Treasury yields hit 24-year highs
Seeking Alpha
·
1 hour ago
15 dividend stocks beating the S&P 500 as markets sit near record highs
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc